Country Club Bank Trims Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Country Club Bank lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 5.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,658 shares of the company’s stock after selling 153 shares during the period. Country Club Bank’s holdings in Eli Lilly and Company were worth $2,333,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Sigma Investment Counselors Inc. boosted its holdings in Eli Lilly and Company by 9.5% in the third quarter. Sigma Investment Counselors Inc. now owns 1,341 shares of the company’s stock valued at $1,188,000 after purchasing an additional 116 shares during the last quarter. Massachusetts Wealth Management boosted its holdings in Eli Lilly and Company by 15.6% in the third quarter. Massachusetts Wealth Management now owns 2,560 shares of the company’s stock valued at $2,268,000 after purchasing an additional 345 shares during the last quarter. Lake Street Advisors Group LLC boosted its holdings in Eli Lilly and Company by 0.7% in the third quarter. Lake Street Advisors Group LLC now owns 10,808 shares of the company’s stock valued at $9,575,000 after purchasing an additional 72 shares during the last quarter. Strategic Investment Solutions Inc. IL raised its stake in Eli Lilly and Company by 8.3% during the third quarter. Strategic Investment Solutions Inc. IL now owns 676 shares of the company’s stock valued at $599,000 after buying an additional 52 shares in the last quarter. Finally, Hudock Inc. raised its stake in Eli Lilly and Company by 0.8% during the third quarter. Hudock Inc. now owns 2,797 shares of the company’s stock valued at $2,478,000 after buying an additional 23 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.2 %

LLY opened at $892.70 on Friday. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market cap of $848.45 billion, a P/E ratio of 109.94, a P/E/G ratio of 3.24 and a beta of 0.42. The stock’s 50 day moving average price is $919.74 and its 200 day moving average price is $862.48.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts predict that Eli Lilly and Company will post 14.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LLY. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. BMO Capital Markets upped their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Citigroup upped their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday. Finally, Berenberg Bank upped their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,013.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.